← All trials
NCT00798070
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2007
- Primary completion
- Apr 1, 2016
- Completion date
- Jan 1, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 2017
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Karolinska InstituteLead sponsor
- Swedish Breast Cancer GroupCollaborator
- Austrian Breast and Colorectal Cancer GroupCollaborator
- German Breast Group Forschungs GmbHCollaborator
- Karolinska InstituteOverall official - principal investigator
- Karolinska InstituteReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.